Erythropoietin for patients with malignant disease

Abstract

There is consistent evidence that the administration of erythropoietin reduces the risk for blood transfusions and the number of units transfused in cancer patients. For patients with baseline haemoglobin below 10 g/dL there is strong evidence that erythropoietin improves haematological response. There is inconclusive evidence whether erythropoietin improves tumour response and overall survival. Research on side effects is inconclusive.

Keywords

ErythropoietinMalignant diseaseDiseaseMedicineCancer researchInternal medicineCancer

Affiliated Institutions

Related Publications

National Institutes of Health Consensus Development Conference Statement: Adjuvant Therapy for Breast Cancer, November 1-3, 2000

Patricia J. Eifel , Jan Axelson , Janitha Costa +11 more

The panel concludes that decisions regarding adjuvant hormonal therapy should be based on the presence of hormone receptor protein in tumor tissues. Adjuvant hormonal therapy sh...

2001 JNCI Journal of the National Cancer I... 894 citations

Cancer treatment and survivorship statistics, 2022

Kimberly D. Miller , Letícia Nogueira , Theresa P. Devasia +5 more

Abstract The number of cancer survivors continues to increase in the United States due to the growth and aging of the population as well as advances in early detection and treat...

2022 CA A Cancer Journal for Clinicians 3548 citations

Publication Info

Year: 2004
Type: review
Issue: 3
Pages: CD003407-CD003407
Citations: 75
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Erythropoietin for patients with malignant disease

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

OpenAlex

Cite This

APA Style

                            
                                    Julia Bohlius, 
                                
                                    Simon Langensiepen, 
                                
                                    Guido Schwarzer
                                
                                et al.
                            
                            (2004). 
                            Erythropoietin for patients with malignant disease. 
                            Cochrane Database of Systematic Reviews
                            
                            (3)
                            , CD003407-CD003407.
                            https://doi.org/10.1002/14651858.cd003407.pub2

Identifiers

DOI: 10.1002/14651858.cd003407.pub2